Centre François Baclesse
Caen, France
54 recruiting
Showing 1–20 of 75 trials
Recruiting
Phase 2
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
NSCLC Stage IVNSCLC Stage III
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer30 enrolled20 locationsNCT06552234
Recruiting
Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Endometrial Adenocarcinoma
Acrivon Therapeutics350 enrolled91 locationsNCT05548296
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled192 locationsNCT06982521
Recruiting
Phase 3
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Colorectal, Cancer
Canadian Cancer Trials Group834 enrolled55 locationsNCT07152821
Recruiting
Phase 4
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
Metastatic Renal Cell CarcinomaLocally AdvancedRenal Cell Carcinoma (Kidney Cancer)
Centre Francois Baclesse83 enrolled16 locationsNCT07028125
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled311 locationsNCT07063745
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Solid Tumor
Eisai Inc.182 enrolled58 locationsNCT04300556
Recruiting
Phase 2
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
Neuroendocrine TumorsProgressive DiseaseIntestinal Well Differentiated Endocrine Tumor
Institut du Cancer de Montpellier - Val d'Aurelle146 enrolled28 locationsNCT04954820
Recruiting
Phase 3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled284 locationsNCT07218380
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled353 locationsNCT06875310
Recruiting
Phase 2Phase 3
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Ovarian CarcinosarcomaEndometrial Carcinosarcoma
ARCAGY/ GINECO GROUP138 enrolled36 locationsNCT03651206
Recruiting
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
Metastatic Breast Cancer
UNICANCER42,000 enrolled20 locationsNCT03275311
Recruiting
Not Applicable
COsegregation of VARiants in Panel of Genes
Genetic PredispositionGene Mutation-Related Cancer
Institut Curie11,000 enrolled62 locationsNCT01689584
Recruiting
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
Lung Cancer
UNICANCER75,000 enrolled21 locationsNCT03848052
Recruiting
Phase 3
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Cervical CarcinomaAdenocarcinomaAdenosquamous Carcinoma
Institut Claudius Regaud510 enrolled35 locationsNCT05581121
Recruiting
Phase 3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Endometrial Cancer
BioNTech SE480 enrolled156 locationsNCT06340568
Recruiting
Not Applicable
Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted Risk
Unilateral Breast Neoplasms
UNICANCER724 enrolled27 locationsNCT07187726
Recruiting
Phase 2
Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
University Hospital, Clermont-Ferrand95 enrolled30 locationsNCT07205731
Recruiting
Phase 2
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Biliary Tract Cancer
UNICANCER72 enrolled41 locationsNCT06529718
Recruiting
Phase 3
Personalized Medicine for Advanced Biliary Cancer Patients
Biliary Tract Neoplasms
UNICANCER800 enrolled69 locationsNCT05615818